MeiraGTx Holdings plc (NASDAQ:MGTX) Stock Position Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) by 10.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 106,582 shares of the company’s stock after buying an additional 10,217 shares during the quarter. Bank of New York Mellon Corp owned 0.14% of MeiraGTx worth $649,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of MeiraGTx by 11.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,571 shares of the company’s stock worth $101,000 after buying an additional 1,685 shares during the period. SG Americas Securities LLC grew its stake in shares of MeiraGTx by 13.3% in the 4th quarter. SG Americas Securities LLC now owns 22,240 shares of the company’s stock valued at $135,000 after buying an additional 2,617 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of MeiraGTx by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock worth $1,429,000 after purchasing an additional 4,186 shares during the last quarter. DAVENPORT & Co LLC increased its position in MeiraGTx by 6.9% during the fourth quarter. DAVENPORT & Co LLC now owns 77,200 shares of the company’s stock worth $470,000 after buying an additional 5,000 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of MeiraGTx by 0.9% during the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock valued at $2,397,000 after acquiring an additional 5,251 shares during the last quarter. 67.48% of the stock is owned by institutional investors.

MeiraGTx Stock Down 7.2 %

Shares of NASDAQ MGTX opened at $7.23 on Thursday. MeiraGTx Holdings plc has a 52-week low of $3.85 and a 52-week high of $8.75. The stock has a market cap of $570.12 million, a PE ratio of -5.98, a PEG ratio of 0.37 and a beta of 1.23. The business has a fifty day moving average of $6.78 and a two-hundred day moving average of $6.02. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The business had revenue of $21.39 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, equities research analysts expect that MeiraGTx Holdings plc will post -1.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on MGTX shares. Chardan Capital reiterated a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a report on Monday, February 24th. Royal Bank of Canada boosted their price objective on MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a research report on Monday, March 17th.

Insider Activity at MeiraGTx

In other news, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total transaction of $150,960.00. Following the completion of the transaction, the chief financial officer now directly owns 849,947 shares in the company, valued at approximately $5,346,166.63. The trade was a 2.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Alexandria Forbes sold 35,839 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total transaction of $231,878.33. Following the transaction, the chief executive officer now owns 1,395,102 shares of the company’s stock, valued at approximately $9,026,309.94. This represents a 2.50 % decrease in their position. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by company insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.